Schering opens south China's premier IUD (intrauterine devices) plant:
This article was originally published in Clinica
The first intrauterine devices (IUD) manufacturing plant in the south of China became operational last week. Berlin-based Schering, whose 2001 product sales in China totalled E24 million ($21million), has invested E3.3 million into the Guangzhou-based plant. It marks the third development in Schering's series of production projects in China. The company has 400 employees in China.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.